Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations
Key Points
mTOR inhibitor treatment shows promise for managing actionable alterations in epithelioid angiomyolipoma.
The presence of biallelic TSC2 mutations could guide personalized therapeutic choices effectively.
Comprehensive genomic profiling was utilized to identify TSC2 mutations, indicating tailored treatment strategies.
This case emphasizes the need for personalized therapy approaches in patients with specific genetic alterations.
Abstract
This case suggests that CGP can help identify actionable alterations in eAML, such as TSC2 mutations, to guide personalized therapy with mTOR inhibitors.